Inari Medical, Inc. (NARI)
Stock Price:
$53.20 USD
2.26 (4.44%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.56B |
| Revenue (ttm) |
71.14M |
| Net Income (ttm) |
-1.19M |
| Shares Out |
48.18M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$53.20 |
| Previous Close |
$50.94 |
| Change ($) |
2.26 |
| Change (%) |
4.44% |
| Day's Open |
50.84 |
| Day's Range |
49.46 - 54.49 |
| Day's Volume |
356,477 |
| 52-Week Range |
39.55 - 54.86 |
More Stats
| Market Cap |
2.56B |
| Enterprise Value |
2.56B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.18M |
| Float |
2.20M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.37 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
162,709 |
| Short Ratio |
0.04 |
| Short % of Float |
0.21% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
36.03 |
| PB Ratio |
n/a |
| Revenue |
71.14M |
| Operating Income |
801,494 |
| Net Income |
-1.19M |
| Free Cash Flow |
-8.08M |
| Net Cash |
4.55M |
| Net Cash / Share |
0.09 |
| Gross Margin |
63.69% |
| Operating Margin |
1.13% |
| Profit Margin |
-2.30% |
| FCF Margin |
-11.36% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-1.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
1 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$54.25*
(1.97% upside)
Low
49.0
Current: 53.20
High
60.0
Target: 54.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 51.13 | 6.83 |
| Revenue Growth | 648.73% | - |
| Gross Profit | 45.22 | 5.55 |
| Operating Income | 0.80 | -9.14 |
| Net Income | -1.19 | -10.15 |
| Shares Outstanding | 5.89 | 5.06 |
| Earnings Per Share | -0.20 | -2.01 |
| Operating Cash Flow | -4.94 | -10.89 |
| Capital Expenditures | -3.14 | -0.75 |
| Free Cash Flow | -8.08 | -11.64 |
| Cash & Equivalents | 24.03 | 21.88 |
| Total Debt | 19.48 | 9.84 |
| Net Cash / Debt | 4.55 | 12.05 |
| Assets | 44.55 | 26.90 |
| Liabilities | 29.52 | 12.18 |
| Book Value | -39.14 | -39.45 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Inari Medical, Inc. |
| Country |
United States |
| Employees |
240 |
| CEO |
William H. Hoffman |
Stock Information
| Ticker Symbol |
NARI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: NARI |
| IPO Date |
May 22, 2020 |
Description
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.